1. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. (1st November 2018) Authors: Maughan, Benjamin L.; Pal, Sumanta K.; Gill, David; Boucher, Kenneth; Martin, Christopher; Salgia, Meghan; Nussenzveig, Roberto; Liu, Ting; Hawks, Josiah L.; Batten, Julia; Nachaegari, Gayatri; Stephenson, Robert; Lowrance, William; Jones, Jeremy; Dechet, Christopher; Agarwal, Neeraj Journal: Oncologist Issue: Volume 23:Number 12(2018) Page Start: 1413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. (2019) Authors: Twardowski, Przemyslaw; Wong, Jeffrey Y.C.; Pal, Sumanta K.; Maughan, Benjamin L.; Frankel, Paul Henry; Franklin, Kelly; Junqueira, Maribel; Prajapati, Manisha R.; Nachaegari, Gayatri; Harwood, Deborah; Agarwal, Neeraj Journal: Cancer treatment and research communications Issue: Number 19(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗